ABBVIE
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 214
- Registration Number
- NCT05969223
- Locations
- ๐บ๐ธ
U.S. Dermatology Partners Longview /ID# 266325, Longview, Texas, United States
๐บ๐ธCare Access - Danville /ID# 266300, Danville, Virginia, United States
๐บ๐ธMedical Dermatology Specialists /ID# 262915, Phoenix, Arizona, United States
An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
- Conditions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT05959070
- Locations
- ๐ง๐ช
Dermatologie Maldegem /ID# 252454, Maldegem, Oost-Vlaanderen, Belgium
๐จ๐ฆJRB Research /ID# 253877, Ottawa, Ontario, Canada
๐ฉ๐ชDermatologische Praxis Dr. med. Marvin Kuske /ID# 265688, Dresden, Germany
Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
- Conditions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT05959083
- Locations
- ๐จ๐ณ
Huashan Hospital, Fudan University /ID# 256456, Shanghai, Shanghai, China
๐จ๐ณThe second affiliated hospital of Zhejiang University school of medicine /ID# 257723, Hangzhou, Zhejiang, China
๐จ๐ณShanghai Skin Disease Hospital /ID# 257719, Shanghai, Shanghai, China
Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting
- Conditions
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 423
- Registration Number
- NCT05956483
- Locations
- ๐บ๐ธ
Richard Louis Price, M.D., LLC /ID# 253527, Monsey, New York, United States
๐บ๐ธHealth Synergy Clinical Research LLC /ID# 262998, Okeechobee, Florida, United States
๐บ๐ธATP Clinical Research, Inc /ID# 255223, Costa Mesa, California, United States
Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity
- Conditions
- Interventions
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1
- Registration Number
- NCT05956509
- Locations
- ๐บ๐ธ
New England Institute for Clinical Research /ID# 255020, Stamford, Connecticut, United States
๐บ๐ธJEM Research Institute /ID# 258782, Lake Worth, Florida, United States
๐บ๐ธNorth County Neurology Associates /ID# 256333, Carlsbad, California, United States
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
- Conditions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1200
- Registration Number
- NCT05930275
- Locations
- ๐ฆ๐บ
Monash Health - Monash Medical Centre /ID# 258538, Clayton, Victoria, Australia
๐ง๐ฌMC Higia HB /ID# 267575, Sofiya, Sofia, Bulgaria
๐ง๐ฌUmbal Kaspela /ID# 267562, Plovdiv, Bulgaria
An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
- Conditions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 250
- Registration Number
- NCT05916157
- Locations
- ๐ฏ๐ต
National Center of Neurology and Psychiatry - Kodaira /ID# 267372, Xiaoping City, Tokyo, Japan
๐ฏ๐ตOkatsu Hospital /ID# 262781, Kagoshima-shi, Kagoshima, Japan
๐ฏ๐ตUniversity of tsukuba Hospital /ID# 268353, Tsukuba-shi, Ibaraki, Japan
Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 15
- Registration Number
- NCT05909553
- Locations
- ๐บ๐ธ
Acpru /Id# 255783, Grayslake, Illinois, United States
A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05895266
- Locations
- ๐บ๐ธ
Acpru /Id# 254970, Grayslake, Illinois, United States
Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05892757
- Locations
- ๐บ๐ธ
Bio-Kinetic Clinical Applications, LLC /ID# 255452, Springfield, Missouri, United States
๐บ๐ธIcon /Id# 257525, Salt Lake City, Utah, United States
๐บ๐ธIcon /Id# 257524, San Antonio, Texas, United States